BOCH
CGEM icon

Blue Owl Capital Holdings’s Cullinan Oncology CGEM Stock Holding History

Blue Owl Capital Holdings’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Sell
1,539,764
-370,000
-19% -$5.49M 4.22% 3
2026
Q1 		$27.1M Sell
1,909,764
-441,208
-19% -$5.67M 7.29% 5
2025
Q4 		$24.3M Sell
2,350,972
-160,000
-6% -$1.44M 7.51% 5
2025
Q3 		$14.9M Buy
2,510,972
+125,000
+5% +$915K 4.62% 8
2025
Q2 		$18M Sell
2,385,972
-50,000
-2% -$402K 5.8% 3
2025
Q1 		$18.4M Buy
2,435,972
+65,000
+3% +$624K 5.95% 3
2024
Q4 		$28.9M Buy
2,370,972
+360,000
+18% +$5.17M 6.65% 5
2024
Q3 		$33.7M Sell
2,010,972
-38,200
-2% -$678K 6.49% 5
2024
Q2 		$35.7M Sell
2,049,172
-875,670
-30% -$18.6M 9.94% 1
2024
Q1 		$49.8M Sell
2,924,842
-495,000
-14% -$7.65M 9.96% 2
2023
Q4 		$34.8M Buy
+3,419,842
New +$30.3M 8.33% 3

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Blue Owl Capital Holdings's CGEM Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Cullinan Oncology (CGEM) stake by 19% in Q2 2026, selling an estimated $5.49M and leaving 1,539,764 shares worth $28M. The position accounts for 4.22% of the portfolio, ranked #3.

Blue Owl Capital Holdings first reported a position in CGEM in Q4 2023 and has held it in 11 quarters since. The position peaked at $49.8M in Q1 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Blue Owl Capital Holdings held 1,539,764 shares of Cullinan Oncology worth $28M as of Q2 2026.
  • Blue Owl Capital Holdings sold 370,000 Cullinan Oncology shares in Q2 2026, an estimated $5.49M.
  • Cullinan Oncology made up 4.22% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #3 holding.
  • Blue Owl Capital Holdings first reported a position in Cullinan Oncology in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's Cullinan Oncology position peaked at $49.8M in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.